Discovery of a Potent Dual ALK and EGFR T790M Inhibitor

The mutational activations of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR) are validated oncogenic events and the targets of approved drugs to treat non-small cell lung cancer (NSCLC). Here we report highly potent dual small molecule inhibitors of both ALK and EGFR, p...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Med Chem
Main Authors: Jang, Jaebong, Son, Jung Beom, To, Ciric, Bahcall, Magda, Kim, So Young, Kang, Seock Yong, Mushajiang, Mierzhati, Lee, Younho, Jänne, Pasi A., Choi, Hwan Geun, Gray, Nathanael S.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800871/
https://ncbi.nlm.nih.gov/pubmed/28528303
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejmech.2017.04.079
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados